A few lines in the
But when you think about it, it becomes clear that CBD oils cannot be treated as Schedule I substances. And here are the four major reasons why the DEA should revise the way it treats cannabinoids.
CBD has medicinal value
According to DEA, Schedule I substances are defined as the ones that have “no currently accepted medical use” and have a high potential for abuse. It may be true for the substances like heroin or LSD, but it is definitely a lie when it comes to cannabinoids. A whole spectrum of studies and numerous medical cannabis patients show that cannabis oils, and in particular CBD oils, may be helpful to people suffering from cancer, breast cancer, or even severe forms of epilepsy.
All these examples show that CBD helps people and does not seem to hurt them. But the DEA’s statement denies the medicinal potential of cannabinoid and continues to insist that CBD is as harmful as other Schedule I drugs are.
Government research shows CBD has medical benefit
Along with numerous studies funded by marijuana activists or businesses, there are a lot of projects that were sponsored by the government. In 2015, for instance, the NIH supported over 280 projects and spent over $111 million on cannabinoid research. At least 15 of that projects were focused on CBD only.
CBD is not psychoactive or addictive
Unlike THC (the second most famous cannabis component), CBD has no psychoactive effects and does not make you high. The cannabinoids in cannabis and hemp are not addictive either. In fact, marijuana is believed to be helpful when it comes to fighting addictions to other substances like alcohol, tobacco, opioids, or even heroin. Furthermore, there are a lot of substances that are nearly as addictive as heroin, yet they are not prohibited on the federal level.
Changing CBD status within the DEA’s purview
There are a few experts who believe DEA has overstepped its authority in its ruling on marijuana extracts and CBD oils in particular. This agency is supposed to carry out the law, not to create it. So, CBD oil producers and patients are clearly entitled to go to court and fight for their businesses or their right to get the medicine they need.
On the other hand, some lawmakers and marijuana industry professionals admit that what DEA did was not an act of war towards medical marijuana patients or businesses. What DEA did was just clarifying the legal status of the plant that is still prohibited on the federal level.